Pancreas cancer treatment: A surgeon's perspective today
نویسندگان
چکیده
منابع مشابه
Pancreas cancer treatment: a surgeon's perspective today.
In 1968 John Howard, one of the pioneers of pancreatic surgery, reported the first series of patients submitted to pancreatic resectionwithout mortality. This contributed to reduce skepticism about pancreas surgery and to open a new surgical era. Nowadays, perioperative mortality after pancreaticoduodenectomy in high-volume centers does not exceed 2–3% of cases, and the goal of zeromortality su...
متن کاملHyperthermia today: electric energy, a new opportunity in cancer treatment.
Hyperthermia is an ancient, but nowadays rapidly developing treatment method in tumor-therapy. Its new paradigm applied in the electro-hyperthermia (oncothermia), which provides energy by means of electric-field and produces non-equilibrium thermal situation in the tissue. The temperature gradients formed in stationary conditions, destroy the membrane of the malignant cells and selectively elim...
متن کاملMarket E¢ ciency Today - A Market Perspective
Economists have long been fascinated by the sources of variations in the stock market. By the early 1970s a consensus had emerged among nancial economists suggesting that stock prices could be well approximated by a random walk model and that changes in stock returns were basically unpredictable. Fama (1970) provides an early, de nitive statement of this position. Historically, the random wa...
متن کاملVaccines today, vaccines tomorrow: a perspective
Vaccines are considered as one of the major contributions of the 20th century and one of the most cost effective public health interventions. The International Vaccine Institute has as a mission to discover, develop and deliver new and improved vaccines against infectious diseases that affects developing nations. If Louis Pasteur is known across the globe, vaccinologists like Maurice Hilleman, ...
متن کاملTreatment of Pancreatic Cancer: What Can We Really Predict Today?
Managing pancreatic cancer remains a big challenge due to its worse course and prognosis. However, therapeutic options and multimodal strategies are increasing nowadays, including new agents, new regimens and chemoradiation. Recently, the FOLFIRINOX regimen has been reported to be more active than gemcitabine in selected metastatic patients. In this setting, it will be of utmost interest to gui...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Surgery
سال: 2012
ISSN: 1743-9191
DOI: 10.1016/j.ijsu.2012.03.004